Oxyphilic Adenoma (Oncocytoma)

A usually benign glandular tumor composed of oxyphil cells, large cells with small irregular nuclei and dense acidophilic granules due to the presence of abundant MITOCHONDRIA. Oxyphil cells, also known as oncocytes, are found in oncocytomas of the kidney, salivary glands, and endocrine glands. In the thyroid gland, oxyphil cells are known as Hurthle cells and Askanazy cells.

Also Known As:

Networked: 265 relevant articles (8 outcomes, 21 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Renal Cell Carcinoma (Grawitz Tumor)
3.	Carcinoma (Carcinomatosis)
4.	Pleomorphic Adenoma
5.	Adenoid Cystic Carcinoma (Cylindroma)

Experts

1.	Yang, Ximing J: 7 articles (01/2010 - 03/2005)
2.	Amin, Mahul B: 5 articles (02/2009 - 01/2005)
3.	Kahl, Philip: 4 articles (01/2015 - 11/2010)
4.	Büttner, Reinhard: 4 articles (01/2015 - 11/2010)
5.	Shen, Steven S: 4 articles (12/2012 - 07/2005)
6.	Sugimura, Jun: 4 articles (01/2010 - 03/2005)
7.	Russo, Paul: 3 articles (01/2016 - 03/2004)
8.	Oliveira, Jorge: 3 articles (11/2015 - 01/2007)
9.	Lobo, Francisco: 3 articles (11/2015 - 01/2007)
10.	Henrique, Rui: 3 articles (11/2015 - 01/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Oxyphilic Adenoma:

1.	Clear-cell metastatic renal cell carcinomaIBA 05/01/2013 - "Thresholding of enhancement helped to discriminate clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC with accuracies of 77% (83 of 108 cases), 85% (101 of 119 cases), and 84% (81 of 97 cases). " 09/01/2015 - "Our study suggests that clear cell RCC has the thickest pseudocapsule while oncocytoma has a poorly developed pseudocapsule, but shows the least infiltrative pattern. " 11/01/2014 - "Clear cell RCC had greater deenhancement than oncocytoma (p < 0.001); deenhancement less than 50 HU or relative corticomedullary attenuation greater than 0% differentiated clear cell RCC from oncocytoma with a positive predictive value of 90%. " 08/01/2013 - "Pax-2 is commonly expressed in the most prevalent renal cell tumour (RCT) subtypes-clear cell RCC (ccRCC), papillary RCC (pRCC) and oncocytoma--but not in chromophobe RCC (chrRCC), which frequently displays chromosome 10 loss (to which PAX2 is mapped). " 05/01/2013 - "Enhancement at multiphasic multidetector CT, if prospectively validated, may assist in the discrimination of clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC."
2.	VimentinIBA 01/01/2015 - "Vimentin 3, the new hope, differentiating RCC versus oncocytoma." 01/01/2009 - "A panel of EABA, vimentin, and RCCma markers can be useful in discerning oncocytoma from RCC with G/E features. " 01/01/2009 - "Vimentin and RCCma were positive in most RCC with G/E features (conventional, 78% and 71%; and papillary, 85% and 76%, respectively), and negative in oncocytoma. " 06/01/2002 - "Thirteen (13) cases of oncocytoma were characterized by the diversity of the structures including to be nest, tubular and papillary in pattern; a mixture of cell types including the classic oncocytes, oncoblasts and clear cells which were negative for vimentin and CK7 but positive for EMA. " 01/01/1992 - "In CRCC and oncocytoma all tumour cells expressed cytokeratins and, in addition, single tumour cells also expressed vimentin. "
3.	ParaffinIBA 12/01/2005 - "FISH techniques on paraffin tissue sections may help to identify genetic aberrations such as CCND1 rearrangement in order to establish a diagnosis of oncocytoma." 12/01/2005 - "FISH in paraffin tissue sections revealed a rearrangement of CCND1 (11q13) in the oncocytoma cells. " 09/01/1991 - "The mES 13 antibody should be useful in the characterization and diagnosis of tumors in which oncocytoma is in the differential diagnosis, especially when only paraffin-embedded tissue is available for study." 11/01/2008 - "Tissue microarrays were created from paraffin-embedded tissue samples from 141 patients with renal cell carcinomas or oncocytoma (90 clear cell, 22 papillary, 17 chromophobe renal cell carcinomas, and 12 oncocytomas). " 05/01/2008 - "We analyzed 20 paraffin-embedded tissues representing clear cell, papillary renal and chromophobe renal cell carcinoma, as well as oncocytoma with Affymetrix GeneChip 10K 2.0 Mapping arrays. "
4.	Caveolin 1IBA 03/01/2006 - "These results strongly suggest that caveolin-1 immunohistochemical analysis is useful for differentiating ChRCC from oncocytoma and is superior to CK7." 02/01/2011 - "Our study was performed to identify whether caveolin-1 and MOC-31 are useful immunohistochemical markers for differentiating chromophobe RCC from oncocytoma. " 02/01/2011 - "There was a statistically significant difference in the expression of caveolin-1 and MOC-31 between chromophobe RCC and oncocytoma (p<0.001). " 05/01/2003 - "There was a statistically significant difference in the expression of caveolin-1 between oncocytoma with a mean labeling index of 91.7 and the cases of malignant renal tumors with a mean labeling index of 26.9 for RCC, 24 for CDC, 21 for CRCR, and 19.2 for PCC. " 02/01/2011 - "Caveolin-1 and MOC-31 can be useful markers in the differential diagnosis of chromophobe RCC, oncocytoma, and clear cell RCC."
5.	MicroRNAs (MicroRNA)IBA 05/01/2012 - "Conversely, miRNA 15a is up-regulated in RCC and down-regulated in oncocytoma. " 05/01/2011 - "miRNA microarray analysis was performed on fresh frozen tissues of three common RCC subtypes (clear cell, chromophobe, and papillary) and on oncocytoma. " 09/01/2010 - "Clustering revealed similarity in microRNA expression between oncocytoma and chromophobe subtypes as well as between conventional (clear-cell) and papillary tumors. " 11/01/2011 - "In particular, great promise for reliable and specific characterization of renal tumor subtypes, such as clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma, is offered - according to the recently presented work by Powers et al. - by a miRNA-profiling method. " 05/01/2012 - "Up-regulated miRNA 15a can be measured in urine from patients with RCC but is nearly undetectable in oncocytoma, other tumors, and urinary tract inflammation. "
6.	imatinib (Gleevec)FDA Link 05/01/2004 - "Finally, it should be determined whether KIT plays a role in the tumorigenesis of ChRCC and oncocytoma and whether targeted therapy with STI-571, an inhibitor of KIT, could be effective in exceptional cases of ChRCC with metastatic extension or recurrence."
7.	tranilast (N 5')IBA 09/01/2009 - "Surgical resection confirmed RCC in 7 patients in whom preoperative EUS-FNA demonstrated RCC (n = 5) or oncocytoma (n = 1) or was not performed (n = 1). " 01/01/2009 - "Cases of multiple oncocytoma previously identified in radical nephrectomy specimens (n = 5) were reviewed for early lesions of renal oncocytosis by light microscopic analysis and by immunohistochemical studies for p53, bcl2 and MIB-1. " 04/01/2015 - "The most common benign histology was angiomyolipoma (n=10, 56%) followed by oncocytoma (n=5, 28%). " 04/01/2002 - "The aims of this study were to determine the frequency and pattern of Mcm2 expression by immunohistochemistry in normal kidney (n = 10) and renal tumors [n = 56; clear cell n = 36; chromophil (papillary) n = 7; oncocytoma n = 5; and transitional cell carcinoma n = 8], compare its sensitivity to the established proliferation marker Ki-67, examine for differences in tumors derived from stable and labile epithelial cell populations in the kidney, and assess the relationship of Mcm2 proliferation to clinicopathological characteristics of kidney tumors. " 06/15/1992 - "The means (range) of the staining intensities of the different types of RCC: clear cell carcinoma Grade 1 (n = 3), 2.0 (2.0 to 2.0); clear cell carcinoma Grade 2 (n = 19), 0.8 (0.0 to 2.9); clear cell carcinoma Grade 3 (n = 5), 0.1 (0.0 to 0.2); tubular carcinoma (n = 4), 2.0 (2.0 to 3.0); anaplastic carcinoma (n = 8), 0.05 (0.0 to 0.2); oncocytoma (n = 1), 0.0 (0.0 to 0.0); and normal kidney (n = 40), 0.5 (0.0 to 2.0). "
8.	Histones (Histone)IBA 12/01/2010 - "The histone acetylation pattern was not different among the diverse histological subtypes of RCC or oncocytoma samples. " 11/15/2010 - "Our study was performed to evaluate histone H3 lysine 4 mono-methyl (H3K4me1), -di-methyl (H3K4me2) and -trimethyl (H3K4me3) patterns in renal cell carcinoma (RCC) using a tissue microarray with 193 RCC (including 142 clear cell, 31 papillary, 10 chromophobe and 10 sarcomatoid RCC) and 10 oncocytoma specimens: H3K4me3 staining was more intense in papillary RCC, whereas H3K4me1 and H3K4me2 were similar in the diverse RCC subtypes. " 12/01/2010 - "Global histone acetylation levels (histone H3 lysine 9 acetylation [H3K9Ac], histone H3 lysine 18 acetylation [H3K18Ac], total histone H3 acetylation [H3Ac] and total histone H4 acetylation [H4Ac]) were determined in patients with renal cell carcinoma (RCC) using immunohistochemistry in a tissue micro array with 193 RCC and 10 oncocytoma specimens. " 11/02/2015 - "Hence, the main goal of this study was to identify differentially expressed histone methyltransferases (HMTs) and histone demethylases (HDMs) that might prove useful for RCT diagnosis and prognostication, emphasizing the discrimination between oncocytoma (a benign tumor) and renal cell carcinoma (RCC), especially the chromophobe subtype (chRCC). "
9.	renal OncocytomaIBA 07/01/2015 - "The immunohistochemical profile of small cell variant of renal oncocytoma is partially consistent with classic oncocytoma, expressing EMA, CK18, CD117 and E-cad. " 07/01/2013 - "Telangiectatic oncocytoma: a previously undescribed variant of renal oncocytoma." 11/01/2011 - "A cohort of a heretofore not described rare subtype of renal oncocytoma, small cell oncocytoma with pseudorosettes is presented. " 12/01/2010 - "The recognition of the spectrum of morphological changes observed in renal oncocytoma should help pathologists establish a diagnosis of oncocytoma in problematic cases." 01/01/2010 - "A cytogenetic alteration, loss of chromosome 1p, common to renal oncocytoma and chRCC has been identified, providing the opportunities for identifying novel tumor suppressor genes and we have identified a series of immunohistochemical markers that are clinically useful in discriminating chRCC and oncocytoma."
10.	Formaldehyde (Formol)FDA Link 09/15/2005 - "In the formalin-fixed group, the molecular criteria accurately classified the cases into 15 clear cell, 16 papillary, and 32 in the chromophobe/oncocytoma group but could only separate some, but not all, oncocytomas from chromophobe RCC. " 08/01/2010 - "The aim of this study was to examine the value of electron microscopy in differentiating between oncocytoma and chromophobe renal cell carcinoma on formalin fixed paraffin embedded needle core biopsies. " 06/01/2011 - "The miRNA expression was analyzed from formalin-fixed paraffin-embedded tissue in 5 cases each of oncocytoma, ccRCC, papillary RCC, chRCC, and 4 normal kidney tissues using microarrays. " 01/01/1984 - "Buffered-formalin fixed, paraffin embedded sections of Warthin's tumor, cystadenoma, oncocytoma, autoimmune thyroiditis, normal salivary gland, and reactive peripheral lymph node were obtained and processed via the peroxidase-antiperoxidase method following trypsinization to re-expose antigenic sites. " 10/31/2012 - "Formalin-fixed, paraffin-embedded tissues of surgically resected renal tumors (chromophobe RCC, 14 cases [10 cases of classic type and 4 cases of eosinophilic variant]; oncocytoma, 7 cases; and clear cell RCC, 9 cases) and kidneys from immature infants (4 cases) were immunostained with antibodies against sialyl glycoproteins (anti-KL-6 and anti-sialyl MUC1 antibodies). "

Therapies and Procedures

1.	Adrenalectomy 01/01/2007 - "We present a case of adrenal oncocytoma in a hypertensive male who had elevated catecholamine levels, which improved after adrenalectomy with decrease in daily antihypertensive requirement." 01/01/2014 - "Laparoscopic adrenalectomy was performed and the mass was pathologically confirmed as adrenocortical oncocytoma of uncertain malignant potential. " 01/01/2009 - "Laparascopic left adrenalectomy and subsequent pathologic examination demonstrated a 8×6.5×4 cm oncocytoma. " 10/01/2008 - "We report a rare case of adrenal oncocytoma that was functional and was successfully managed by laparoscopic adrenalectomy." 06/01/2008 - "Laparoscopic transperitoneal adrenalectomy for adrenocortical oncocytoma."
2.	Nephrectomy 11/01/2014 - "We report the case of an asyptomatic 74-year-old man with papillary RCC within oncocytoma managed with left radical nephrectomy. " 01/01/2014 - "We report the first case of partial nephrectomy in a 45-year-old man who presented with a 20-cm oncocytoma. " 07/01/2012 - " renal mass biopsy is the only way for pre-nephrectomy histologic diagnosis of oncocytoma." 01/01/2010 - "A hybrid oncocytoma was detected which was surgically excised by partial nephrectomy. " 04/01/2007 - "The incidental finding of a papillary RCC located in an oncocytoma in a nephrectomy specimen from a 75-year-old man is described. "
3.	Transplants (Transplant) 02/01/2004 - "Nephrotic range proteinuria in a renal transplant associated with oncocytoma of the native kidney." 07/01/2012 - "Development of spontaneous retroperitoneal hematoma caused by rupture of the native kidney oncocytoma was complicated with sepsis and deterioration of graft function. "
4.	Radiotherapy 07/01/1979 - "A case of a slowly-growing, low-grade malignant oncocytoma of the nasal cavity in a 50-year-old male, with no lymph node or distant metastases or local invasion of vital adjacent structures, and treated with combined radiotherapy and radical surgery, has been presented. " 12/01/1998 - "Tumor progression after radiotherapy occurred significantly more often (p=0.0397) in patients with oncocytoma than in patients with nononcocytic null cell adenoma. "
5.	Renal Dialysis (Hemodialysis) 11/01/1992 - "Of these 27 patients, 22 patients including one patient under hemodialysis treatment had renal cell carcinoma and one patient had oncocytoma pathologically proven from the excised specimens. " 11/01/1988 - "Acquired renal cystic disease was noted in 4 of the 7 cases (57 per cent) and renal neoplasia was evident in all 7. Worldwide experience to date in combined pathology and radiology series of patients undergoing hemodialysis demonstrates that acquired cystic disease, "tumor" (usually adenoma or oncocytoma) and renal carcinoma occur at respective rates of 47.1, 4.8 and 1.5 per cent. "